Clinical Trial · NCT05246475

Measurement of Head and Neck Tumor Hypoxia With PET-MRI

Overview

This study is designed to evaluate the performance of advanced magnetic resonance (MR) imaging in the assessment of tumor hypoxia using \[18F\]EF5 positron emission tomography (PET) as a reference in head and neck cancer patients. Low oxygen level or hypoxia contributes to radiotherapy resistance. Therefore, a clinically applicable method to detect tumor hypoxia is of great importance.

Sponsor

Turku University Hospital

Phase

N/A

Contacts

Jussi Hirvonen, MD, PhD (CONTACT)

jussi.hirvonen@tyks.fi

0035823130000

Jussi Hirvonen, MD, PhD (PRINCIPAL_INVESTIGATOR)

Antti Silvoniemi, MD, PhD (CONTACT)

antti.silvoniemi@tyks.fi

0035823130000

ClinicalTrials.gov

NCT05246475

Eligibility

Inclusion

Primary tumor diameter as determined clinically or from contrast enhanced CT or MRI scan must be at least 20 mm
Patients with nodal neck metastases of head and neck cancer are eligible
Diagnosis: Histological, cytological and clinical findings are consistent with squamous cell carcinoma of the head and neck (oral cavity, pharynx or larynx)

Exclusion

Advanced disease: Patient is not eligible for curative cancer treatment due to advanced disease.
Prior Medical History: Patient must have no history of serious haematologic, cardiovascular, liver or kidney disease. Since none of these is an absolute contraindication for inclusion final judgement will be left to the investigators.
Prior Therapy: Patient must have no history of previous chemotherapy, biological therapy, immunotherapy, radiotherapy or major surgery for treatment of head and neck cancer